---
title: "關於榮昌生物股份有限公司在2025年12月15日宣佈的股票回購計劃的分期更新"
description: "從 2026 年 1 月 1 日到 2026 年 1 月 20 日，公司回購了 194,144 股，代表 0.04%，回購金額為 2000 萬元。至此，公司已完成於 2025 年 12 月 15 日宣佈的回購計劃，共回購 194,144 股，代表 0.04%，回購金額為 2000 萬元"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273231494.md"
published_at: "2026-01-21T12:40:28.000Z"
---

# 關於榮昌生物股份有限公司在2025年12月15日宣佈的股票回購計劃的分期更新

> 從 2026 年 1 月 1 日到 2026 年 1 月 20 日，公司回購了 194,144 股，代表 0.04%，回購金額為 2000 萬元。至此，公司已完成於 2025 年 12 月 15 日宣佈的回購計劃，共回購 194,144 股，代表 0.04%，回購金額為 2000 萬元

From January 1, 2026 to January 20, 2026, the company has repurchased 194,144 shares, representing 0.04% for CNY 20 million. With this, the company has completed the repurchase of 194,144 shares, representing 0.04% for CNY 20 million under the buyback announced on December 15, 2025.

### Related Stocks

- [588130.CN - 華夏上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [09995.HK - 榮昌生物](https://longbridge.com/zh-HK/quote/09995.HK.md)
- [688331.CN - 榮昌生物](https://longbridge.com/zh-HK/quote/688331.CN.md)
- [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [159849.CN - 招商中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [588250.CN - 鵬華上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [516500.CN - 華夏中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [510660.CN - 華夏醫藥ETF](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [512290.CN - 國泰中證生物醫藥ETF](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [516820.CN - 平安中證醫療創新ETF](https://longbridge.com/zh-HK/quote/516820.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-HK/news/276024005.md) |
| RemeGen Lifts Price Cap on Share Repurchase | RemeGen Lifts Price Cap on Share Repurchase | [Link](https://longbridge.com/zh-HK/news/272783447.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。